Nergie Sant Chakra

https://www.cancer.gov › news-events › cancer-currents-blog › fda...
FDA has approved zenocutuzumab Bizengri to treat lung and pancreatic cancers with a rare genetic alteration called an NRG1 fusion

https://www.fda.gov › drugs › resources-information...
On December 4 2024 the FDA granted accelerated approval to zenocutuzumab zbco for non small cell lung cancer and pancreatic adenocarcinoma

https://www.managedhealthcareexecutive.com › view › trial-supports...
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion positive cancers adding support for Bizengri zenocutuzumab as a promising

https://www.lungcancerresearchfoundation.org › accelerated-approval...
The good news The U S Food and Drug Administration FDA has granted accelerated approval to zenocutuzumab zbco for the treatment of adult patients with

https://www.biospace.com › press-releases › zenocutuzumab-zbco...
In December 2024 zenocutuzumab zbco BIZENGRI received U S Food and Drug Administration accelerated approval for the treatment of adults with advanced

https://www.cancernetwork.com › view › zenocutuzumab...
Zenocutuzumab zbco Bizengri showed potential in patients with treatment naive non small cell lung cancer NSCLC harboring an NRG1 gene fusion in results from a post

https://www.mskcc.org › news › fda-approves-zenocutuzumab-for...
The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non small cell lung cancer with an alteration called an

https://www.cancer-research-network.com › fda-approves...
On 4 December 2024 FDA granted accelerated approval to zenocutuzumab zbco Bizengri for the treatment of adults with advanced unresectable or metastatic non small

https://www.onclive.com › view
NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer leading to the FDA approval of zenocutuzumab in December 2024